Metrics as of 10/17/2026, 03:22 AM (Berlin time), refresh in progress.
Helix BioPharma Stock
Helix BioPharma Corp.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- CEO
- Thomas Mehrling
- Employees
- 7
- Market cap
- $75 M
- IPO
- 13/08/1996
Based in Richmond Hill, Canada, Helix BioPharma Corp. is a Canadian immune-oncology company focused on therapeutic development. The firm is progressing L-DOS47 for treating non-small cell lung cancer and is also working on V-DOS47, which targets the vascular epithelial growth factor receptor 2. Helix BioPharma has…
Helix BioPharma stock: price history
1D
+7.7%
1W
+6.5%
1M
-30.0%
6M
-50.8%
YTD
-58.6%
1Y
-60.5%
2Y
-26.9%
5Y
-66.2%
10Y
-87.4%
Next earnings date
Next earnings date
29/10/2026 (in 12 days)
Volatility around earnings
~15% stronger price swings than usual
Ask the agents about Helix BioPharma
Helix BioPharma stock metrics
P/E
-22.27
P/B
5.1
EV/EBITDA
-23.47
RETURN ON EQUITY
-4.6%
NET MARGIN
0.0%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
30/04/2026
Free float & liquidity
FREE FLOAT
65.9%
FLOAT SHARES
50,343,479
AVG. DAILY VOLUME (30D)
12,930
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Helix BioPharma stock
What does Helix BioPharma do?
Helix BioPharma Corp. is a company in the Healthcare sector, Biotechnology industry, headquartered in Canada.
The CEO is Thomas Mehrling, the company employs around 7 people.
The IPO was on 13/08/1996; the stock trades on TSX under the ticker HBP.TO.
When does Helix BioPharma report next?
The next earnings date is 29/10/2026.
Around past earnings, price swings were roughly 15% stronger than usual.
Does Helix BioPharma pay a dividend?
No, Helix BioPharma currently does not pay a dividend.
Which stocks are comparable to Helix BioPharma?
Comparable stocks include AbCellera Biologics, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get Helix BioPharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess Helix BioPharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.